Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy

Authors

  • A.M. Barnacle BM, MRCP, FRCR,

    1. Department of Radiology, Great Ormond Street Hospital for Children, London WC1N 3JH, United Kingdom
    Search for more papers by this author
  • Kieran McHugh FRCR, FRCRI, DCH

    Corresponding author
    1. Department of Radiology, Great Ormond Street Hospital for Children, London WC1N 3JH, United Kingdom
    • Department of Radiology, Great Ormond Street Hospital for Children, Great Ormond Street, London WC1N 3JH, UK.
    Search for more papers by this author

Abstract

Background

Response evaluation criteria in solid tumors (RECIST) guidelines were published in 2000 to evaluate response to treatment in solid tumors. These have sought to unify response assessment, and the new guidelines extend beyond lesion assessment to address modern imaging strategies. The RECIST guidelines, however, become complex and problematic when used to evaluate metastatic disease.

Methods

Ten consecutive oncology cases representative of tumors common to our pediatric practice were selected. All cases were evaluated at initial presentation and follow-up. The RECIST criteria were retrospectively applied in each case. A standardized evaluation form was used.

Results

The age range of the patients included in the study was 1 month to 16 years, with a mean age of 3.9 years. A range of tumor responses was identified: partial response (n = 6), stable disease (n = 2), and progressive disease (n = 2). Two of these responses were likely incorrect. Tumor bulk was underestimated in the axial plane, many lesions were either calcified and unmeasurable, or despite being well-defined were too small to be measurable under the strict RECIST guidance.

Conclusion

In highlighting specific problems with disseminated pediatric tumors, we emphasize the pressing need for debate regarding the application of RECIST in pediatric oncology and encourage the development of a pediatric radiology oncology group to collaborate in future modifications of the RECIST guidance. Pediatr Blood Cancer. © 2005 Wiley-Liss, Inc.

Ancillary